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Key points
●● Respiratory distress is a common presenting feature among newborn infants.
●● Prompt investigation to ascertain the underlying diagnosis and appropriate subsequent 
management is important to improve outcomes.
●● Many of the underlying causes of respiratory distress in a newborn are unique to this age group.
●● A chest radiograph is crucial to assist in diagnosis of an underlying cause.
Educational aims
●● To inform readers of the common respiratory problems encountered in neonatology and the 
evidence-based management of these conditions.
●● To enable readers to develop a framework for diagnosis of an infant with respiratory distress.
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The first hours and days of life are of crucial importance for the newborn infant as the infant 
adapts to the extra-uterine environment. The newborn infant is vulnerable to a range of respi-
ratory diseases, many unique to this period of early life as the developing fluid-filled fetal lungs 
adapt to the extrauterine environment. The clinical signs of respiratory distress are important to 
recognise and further investigate, to identify the underlying cause. The epidemiology, diagnostic 
features and management of common neonatal respiratory conditions are covered in this review 
article aimed at all healthcare professionals who come into contact with newborn infants.
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Introduction
The ability of the newborn infant to adapt to 
the extra-uterine environment is critical to sur-
vival. All systems of the body undergo important 
physiological changes at the time of delivery [1]. 
Arguably none is more critical to survival than 
the adaption of the lungs [2]. In utero, the fetus 
receives a constant supply of oxygen and nutri-
ents via the placenta and umbilical vessels, with 
carbon dioxide excretion also managed via the 
maternal circulation. The lungs are filled with 
fluid secreted by the respiratory epithelium [3] 
which is important for promoting lung growth. 
Some congenital malformations of the lungs or 
airways may not affect the fetus or its develop-
ment in utero, even anomalies incompatible with 
extra-uterine life. Hydrops fetalis is a recognised 
complication of larger lesions, including those 
that affect the arterial circulation. During the first 
gasp immediately after birth, the neonate fills the 
airways down to alveolar level with air to com-
mence extra-uterine gas exchange [2]; simulta-
neously, decreasing pulmonary vascular pressure 
to allow increased blood flow to the lungs [4]; 
additionally, reabsorption of the fetal lung fluid 
occurs [5]. A preterm neonate born at <37 weeks’ 
gestation has the additional complication of 
achieving these changes with relatively immature 
lungs. Extremely preterm (⩽28 weeks’ gestation) 
and late preterm neonates (⩽32 weeks’ gesta-
tion) need to survive without adequate alveolar 
development, which generally commences after 
32 weeks’ gestational age [6].
Neonatal respiratory conditions can arise 
for several reasons: delayed adaptation or mal-
adaptation to extra-uterine life, existing condi-
tions such as surgical or congenital anomalies 
or from acquired conditions such as pulmonary 
infections occurring either pre- or post-delivery. 
An Italian study showed that 2.2% of all births 
were complicated by a respiratory disorder [7] 
with an Indian study estimating 6.7% [8]. Respi-
ratory conditions are the most common reason 
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for admission to a neonatal unit in both term 
and preterm infants [9]. One study reported that 
33.3% of all neonatal admissions at >28 weeks’ 
gestation, excluding infants with syndromes and 
those with congenital or surgical conditions, had 
respiratory conditions as their primary reason 
for admission [10]. A  further study estimated 
that 20.5% of all neonatal admissions showed 
signs of respiratory distress [11]. Evidence exists 
of rising rates of neonatal admissions due to 
respiratory conditions, possibly due to the effect 
of increased rates of caesarean section delivery 
[12, 13].
This review distinguishes between those neo-
natal respiratory conditions witnessed primarily 
in preterm infants, those more common in term 
infants and congenital/surgical anomalies, which 
can occur in infants born at any gestation. Table 1 
summaries the most common conditions in each 
category.
Clinical identification and 
initial management of 
respiratory conditions
Thorough clinical assessment of the newborn 
infant is the most important aspect of accurately 
diagnosing the underlying respiratory condition. 
An infant with breathing difficulties displays clas-
sic clinical signs of respiratory distress regard-
less of the underlying cause. These consist of 
tachypnoea (respiratory rate >60 breaths⋅min−1), 
tachycardia (heart rate >160 beats⋅min−1), nasal 
flaring, grunting, chest wall recessions (supra-
sternal, intercostal and subcostal), cyanosis and 
apnoea. First line investigations in the assess-
ment of a neonate with respiratory distress 
should include pulse oximetry, chest radiograph 
and blood tests (full blood count, C-reactive pro-
tein, blood culture and arterial blood gas) [14]. A 
chest radiograph is particularly useful for distin-
guishing the underlying cause. It is important to 
recognise that respiratory distress can be caused 
by non-respiratory pathology such as meta-
bolic acidosis, neuromuscular disorders, cardiac 
causes or hypoxic- ischaemic encephalopathy. 
The scope of this review does not extend to cover 
non-respiratory causes of respiratory distress. 
Some of the important clinical considerations 
that should be made when assessing a newborn 
infant with respiratory distress to assist in diag-
nosing the underlying cause are shown in the box 
to the left [14].
Emergency treatment in cases of neonatal 
respiratory distress is to reverse any hypoxia 
with supplemental oxygen and to prevent or 
reverse any respiratory acidosis by ensuring 
adequate ventilation of the lungs. This may 
require noninvasive respiratory support, such 
as continuous positive airway pressure (CPAP) 
or high flow therapy [15]; or tracheal intubation 
and mechanical ventilation in the most severely 
affected cases. Feeding is generally delayed 
until an underlying diagnosis has been made. 
Further management depends on the under-
lying diagnosis. Antibiotics are often routinely 
prescribed for all infants with respiratory dis-
tress due to the difficulty in excluding respira-
tory infections.
FAQs when assessing an infant with 
respiratory distress
Modified from [14] with permission from the publisher.
Is it a cardiac or respiratory problem?
Consider the need for chest radiograph and echocardiogram.
Is anything else causing the respiratory distress?
Consider metabolic, renal or neurological causes.
What is the gestational age of the baby?
Preterm neonates (<37 weeks) are more likely to have respiratory distress 
syndrome.
Post-term neonates (>42 weeks) are more likely to have meconium aspira-
tion syndrome.
Late preterm and term neonates are more likely to have transient 
 tachypnoea of the newborn.
Is it severe or mild respiratory distress?
Severe distress is more likely with respiratory distress syndrome, meconium 
aspiration syndrome or persistent pulmonary hypertension of the neonate.
Mild distress is more likely with transient tachypnoea of the newborn.
Are there any known congenital anomalies?
Review antenatal scan reports for congenital diaphragmatic hernia, 
 congenital cystic adenomatoid malformation, etc.
What was the delivery method?
Pre-labour section is more likely to be transient tachypnea of the newborn.
Evidence of meconium stained amniotic fluid is more likely to be 
 meconium aspiration syndrome.
Is there poor improvement with increasing oxygen 
flow?
Consider persistent pulmonary hypertension of the neonate or congenital 
cyanotic heart disease in the case of persistent hypoxia and cyanosis 
despite 100% oxygen.
Are there risk factors for sepsis?
Premature rupture of membranes, group B streptococcus on high vaginal 
swab, maternal pyrexia or raised inflammatory markers in maternal blood 
would suggest pneumonia.
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Common conditions seen 
primarily in preterm infants
Respiratory distress syndrome
Epidemiology and risk factors
Respiratory distress syndrome (RDS) is seen pri-
marily in preterm infants due to a deficiency of 
surfactant in the lungs. Often also called hya-
line membrane disease, which more accurately 
is a histological diagnosis. Classically, RDS is 
observed in preterm infants, however, 6.4% [16] 
to 7.8% [17] of cases with RDS are diagnosed in 
infants born at ⩾37 weeks’ gestation, many being 
delivered by caesarean section. Among preterm 
infants, the incidence varies with gestation with 
increasing incidence with decreasing gestations. 
Infants of mothers with diabetes are also at 
increased risk of developing RDS.
Surfactant is produced by type 2 pneumo-
cytes from the 24th week of gestation and levels 
increase with increased gestational age [18]. The 
alveolar pool size of surfactant phospholipids in 
a healthy full-term infant has been estimated to 
be 100 mg⋅kg−1, about ten-times greater than the 
amount noted in lungs of infants who develop 
RDS [19]. The action of surfactant is not limited 
to reducing surface tension of alveolar lining fluid, 
but RDS is primarily a consequence of the failure to 
reduce surface tension within alveoli [20]. Reduced 
surfactant results in increased respiratory effort 
required to expand the lung with each breath and 
increased likelihood of alveolar collapse at the end 
of expiration.
Clinical aspects
Signs of respiratory distress are usually 
present soon after birth. The chest radiograph 
 demonstrates poorly inflated lungs with a “ground 
glass” appearance of reticular nodular shadowing 
throughout the lung fields and air bronchograms 
as demonstrated in figure 1a. The respiratory 
distress worsens over the first 2–3 days of life, 
stabilises for a further 2–3 days before clinically 
improving often with a diuretic phase.
Antenatal maternal administration of corti-
costeroids and exogenous surfactant therapy 
have revolutionised the management of RDS. 
Antenatal corticosteroids result in maturation of 
the fetal lung, by promoting maturation of the 
antioxidant system and of surfactant production; 
prepare the fetal lung for breathing and prevent-
ing or reducing the severity of RDS respectively 
[22]. Mothers are routinely given antenatal cor-
ticosteroids in cases of threatened preterm birth 
[23]. Exogenous surfactant is routinely adminis-
tered prophylactically to preterm infants requir-
ing tracheal intubation at birth to prevent RDS. 
New techniques of delivering surfactant with 
only minimal intubation time, or even without 
the need for an endotracheal tube are increas-
ingly considered in the management of preterm 
infants at risk of developing RDS [24]. Established 
RDS can be treated with further doses of surfac-
tant, but optimal timing of rescue doses of sur-
factant remains unclear [25]. For those infants 
less severely affected maintaining positive end 
expiratory pressure with continuous positive 
airway pressure (CPAP), and using supplemental 
oxygen where necessary is recommended [25]. 
“High-flow” nasal oxygen therapy as an alterna-
tive to CPAP is increasingly used in many units 
but requires careful evaluation [15, 26].
Prognosis
Recovery from RDS is dependent on its severity, 
which, in turn, is affected by gestation and birth 
weight. Historically 50% mortality from RDS was 
seen in infants <1000 g birth weight compared to 
Table 1 Common causes of neonatal respiratory distress
Preterm pathology Term pathology Congenital anomalies/
surgical conditions
Non-respiratory causes 
of respiratory distress
Respiratory distress syndrome
Pneumothorax
Pneumonia
Pulmonary haemorrhage
Aspiration
Pleural effusion (chylothorax)
Chronic lung disease
Transient tachypnoea of the 
newborn
Respiratory distress syndrome
Meconium aspiration
Primary or secondary persistent 
pulmonary hypertension of 
the newborn
Pneumonia
Pneumothorax
Aspiration
Pleural effusion (chylothorax)
Pulmonary haemorrhage
Surfactant protein deficiency 
syndromes
Alveolar capillary dysplasia
Congenital pulmonary airway 
malformation
Congenital diaphragmatic 
hernia
Tracheo-oesphageal fistula
Choanal atresia
Pulmonary sequestration
Congenital lobar emphysema
Heart failure (due to 
congenital heart disease)
Neuromuscular disorders
Hypoxic ischaemic 
encephalopathy
Metabolic acidosis (due 
to inborn error of 
metabolism)
Common respiratory conditions of the newborn
34 Breathe | March 2016 | Volume 12 | No 1
0% in those >4000 g [11]. While RDS is rarely an iso-
lated pathology affecting extreme preterm infants, 
respiratory insufficiency, due to immaturity of the 
lungs, limits viability in extremely preterm infants.
Chronic lung disease
Epidemiology and risk factors
Chronic lung disease (CLD), also often called 
broncho-pulmonary dysplasia (BPD) is the most 
common long-term respiratory consequence of pre-
maturity [27]. CLD is defined as supplemental oxy-
gen dependency for at least 28 days from birth, and 
at 36 weeks corrected gestational age. Often the 
length of supplemental oxygen dependency is used 
to grade severity. Injuries to the developing preterm 
lung result in impaired alveolar and vascular devel-
opment. CLD is known to be a multifactorial condi-
tion with a diverse range of contributing risk factors. 
Extremely preterm born infants are at the highest 
risk. Infants born at 23 weeks’ gestational age have 
an incidence of CLD of 73%, while for those born 
at 28 weeks’ gestation the incidence of CLD is 23% 
[28]. Small-for-gestational-age infants are also at a 
greater risk [29]. The presence of chorioamnionitis, 
mechanical ventilation [30], postnatal sepsis [30], 
oxygen toxicity [31] and fluid overload often due 
to the presence of a patent ductus arteriosus [32] 
are all risk factors for CLD. The common pathway 
for each of these mechanisms is thought to be the 
generation of an inflammatory response within the 
lungs of preterm infants [33]. Many studies show 
excessive inflammatory activity within the lungs 
of preterm infants who progress to develop CLD 
[34–36]. The preterm immune system itself may be 
prone to poorly regulated or excessive inflammatory 
activity contributing to the tissue damage [37, 38].
Despite attempts to modify all variable risk fac-
tors, the rate of CLD has failed to improve, possibly 
due the increased survival of more infants born 
extremely preterm [39]. The introduction of antena-
tal maternal corticosteroids administration and use 
of exogenous surfactant, along with lung protective 
ventilation strategies has, however, seen a in change 
in the pathology from “old CLD” to “new CLD” [40]. 
Old CLD was characterised by marked fibrosis; vary-
ing hyperinflation and atelectasis; and decreased 
alveolarisation [41]. Histologically, new CLD infants 
has less fibrosis, less heterogeneity of lung disease 
but larger, fewer alveoli than its older variant [42].
Clinical aspects
CLD usually evolves in preterm infants from their 
RDS. Treatment of CLD consists of supportive 
a) b)
c) d)
Figure 1 Chest radiograph images. a) Intubated 23+6 weeks preterm infant with RDS. Note bilateral ground glass shad-
owing and air bronchograms. The ET tube is low in this image and needs withdrawing. Parental consent obtained for 
publication. b) Ex 24-week preterm infant with CLD. Note areas of cystic changes and linear shadowing throughout both 
lungs. Parental consent obtained for publication. c) Term infant with TTN. Note wet silhouette around the heart and fluid 
in the horizontal fissure. Image: © Auckland District Health Board. d) Term infant with MAS. Widespread asymmetrical 
patchy shadowing throughout both lungs with hyperinflation. Reproduced from [21] with permission from the publisher.
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management and treating co-morbidities to 
optimise lung function. Oxygen therapy targeted 
to optimise oxygen saturation without causing 
hyperoxic damage is the mainstay of treatment. 
Postnatal corticosteroids are effective at decreas-
ing inflammation within the lung, but the risk of 
neurodevelopmental side-effects limits its use. 
Current practice is to restrict use of corticosteroids 
to aid extubation in those infants who remain 
chronically mechanical ventilation dependent. 
Other therapies, such as diuretics and inhaled cor-
ticosteroids, have limited evidence base [43, 44] 
but are often used in clinical practice. Preventing 
preterm infants from developing CLD by modify-
ing risk factors and optimising clinical care is the 
ultimate aim. Avoidance of tracheal intubation 
and newer methods to administer surfactant non- 
invasively show promise but need careful evalua-
tion before they are routinely used.
The chest radiograph of an infant with CLD 
may display areas of cystic changes, linear inter-
stitial opacities and hyper-expansion of the lungs 
( figure 1b) [45]. However, chest radiograph find-
ings often do not correlate with the clinical sever-
ity in CLD [46].
Prognosis
Short-term consequences of CLD often involve the 
need for home oxygen therapy and a high risk of 
readmission to hospital [27]. CLD infants are often 
diagnosed with “asthma” and suffer recurrent 
wheeze; however, the wheeze is likely to have a 
different underlying cause from that of asthma in 
the general population. At 11 years of age, CLD 
infants have a higher risk of wheeze, use of inhal-
ers and reduced lung function compared with their 
peers [47]. However, the impact of CLD is thought 
to be life-long, with survivors having reduced lung 
function persisting into adulthood [48].
In summary, RDS and CLD are common in 
preterm-born infants; although these infants may 
also develop other respiratory conditions espe-
cially from an infective cause. The routine use of 
antenatal maternal corticosteroids, exogenous 
surfactant and more gentle ventilation methods 
have improved the outcomes, there remains room 
for further improvements.
Common conditions primarily 
seen in term infants
Transient tachypnoea of the 
newborn
Epidemiology and risk factors
Transient tachypnoea of the newborn (TTN) is 
the most commonly diagnosed respiratory con-
dition in term newborn infants [8]. When first 
described in 1966, it was first suggested that the 
self- resolving respiratory distress witnessed most 
often following caesarean section delivery was 
due to a delay in reabsorbing lung fluid [49]. This 
theory continues to be supported today. Delivery 
by caesarean section is the largest risk factor for 
developing TTN, particularly elective caesarean 
sections when mechanisms of labour have not 
commenced [50]. Labour is thought to induce 
the release of maternal catecholamines result-
ing in upregulation of surfactant production and 
trans-epithelial sodium transport causing fluid 
reabsorption in the infant lung [50].
The risk of TTN falls between 37 and 42 weeks’ 
gestation. The concept of early term birth, 
between 37–38 weeks’ gestation, being associ-
ated with higher risk of respiratory conditions has 
recently been described [51]. An increase in both 
early term births and caesarean sections over the 
past 20 years may explain the rise in respiratory 
admissions to neonatal units [13, 17].
It has been suggested that TTN and RDS form 
part of the same spectrum of disease process. 
Evidence suggests that full-term infants with 
TTN may have surfactant deficiency [52] and 
that antenatal maternal administration of cor-
ticosteroids may prevent TTN [53, 54], adding 
weight to this claim. However, the different 
clinical course and distinct chest radiograph 
appearances are evidence for different disease 
processes.  Different findings using lung ultra-
sound can also be detected for the two condi-
tions [55, 56].
Other well-established risk factors for TTN 
include maternal diabetes, maternal asthma, male 
sex, low birth weight and macrosomia [17].
Clinical aspects
An infant with TTN often but not always has 
mild respiratory distress from birth. A chest 
radiograph classically demonstrates a “wet” sil-
houette around the heart and fluid in the hori-
zontal fissure. See figure 1c. The natural history 
of TTN is for self-resolution, so most cases are 
conservatively managed, with investigations 
to exclude more serious underlying causes, 
and supportive treatment using nasal cannula 
oxygen or non- invasive respiratory support as 
needed.
Prognosis
TTN generally has good prognosis. Most classi-
fications of TTN require clinical improvement 
and an end to oxygen supplementation within 
2–3 days to make the diagnosis. Indeed, an 
alternative diagnosis should be sought in cases 
requiring prolonged respiratory support or oxy-
gen supplementation [57]. Two randomised trials 
have sought to reduce the duration of symp-
toms using diuretics, but no benefit has been 
described [58].
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Persistent pulmonary 
hypertension of the newborn
Epidemiology and risk factors
Persistent pulmonary hypertension of the new-
born (PPHN) is characterised by the failure of the 
pulmonary vasculature to adapt to the ex-utero 
environment following birth. PPHN can be pri-
mary or secondary to an associated lung condi-
tion. The incidence of PPHN is approximately one 
per 1000 births [59]. In utero, pulmonary vascu-
lar resistance (PVR) restricts blood flow through 
the lungs allowing blood to be shunted through 
the patent ductus arteriosus (PDA) and foramen 
ovale to the systemic circulation. Following birth, 
the combination of oxygen and respiratory move-
ments facilitate a drop in the PVR [60]. Failure 
of this transition results in persisting high PVR 
resulting in right to left shunting at the level of 
the PDA and foramen ovale, leading to pulmonary 
hypo-perfusion, hypoxia and acidosis [61].
PPHN occurs due to, mal-development, 
under-development or maladaptation [61]. 
Mal-development and under-development are 
commonly associated with congenital defects 
which affect either the lung parenchyma or pul-
monary blood vessels or both, as associated with 
congenital diaphragmatic hernia [62]. Infants 
with maladaptation have normal anatomy but fail 
to adapt to extra-uterine life. Most maladaptation 
is as a consequence of lung parenchymal disease, 
infection or perinatal asphyxia [61]. Maladapta-
tion associated with primary PPHN has also been 
linked with chromosomal or genetic disorders, 
including trisomy 21 [63]; and maternal medica-
tion use during pregnancy, specifically selective 
serotonin uptake inhibitors; although its impor-
tance in the pathogenesis is debated [64].
Clinical aspects
PPHN is difficult to differentiate from cyanotic 
congenital heart disease as presentation is often 
very similar. Definitive diagnosis of PPHN is made 
using echocardiography to exclude cyanotic heart 
disease and estimate pulmonary arterial pres-
sure. However, clinical findings can also assist 
with diagnosis. Right-to-left shunting can be evi-
denced by assessing pre- and post- ductal oxygen 
saturations, where pre- ductal saturations will be 
significantly higher than post-ductal. An oxygen 
requirement disproportionate to radiographic 
findings may suggest PPHN, unless PPHN is sec-
ondary to other respiratory disease [60].
Effective management of PPHN requires rapid 
assessment and active management to reduce 
PVR and address the effect of supra-systemic 
pulmonary pressures in those infants who may 
need multi-organ support. Strategies to optimise 
ventilation, reduce acidosis and eradicate hypoxia 
all contribute to the reversal of PPHN along with 
concurrent treatment of any underlying pathology. 
Continuous vital sign monitoring including pre- and 
post- ductal oxygen saturations and invasive blood 
pressure monitoring is required. Regular repeated 
clinical assessment with blood gas analysis and 
oxygenation index calculation assists in evaluating 
disease severity and response to treatment. Infants 
with PPHN are fragile and intolerant of stimulation 
[65]. Minimal handling, sedation, analgesia and 
induced paralysis are important to help avoid cata-
strophic changes in PVR and  oxygenation.
Administering the potent vasodilator, oxygen, 
is key to reducing PVR. Target oxygen saturations 
are higher than conventional neonatal targets at 
a minimum level of 94% for pre-ductal readings. 
Invasive ventilation assists in optimising alveolar 
recruitment, reducing ventilation/perfusion mis-
match and further reducing PVR. Inhaled nitric 
oxide, an endothelial derivative causing selective 
pulmonary vasodilation, has been demonstrated 
to reduce the need for extracorporeal membrane 
oxidation (ECMO) [66].
The effect of suprasystemic pulmonary pres-
sures is mitigated by reducing PVR. Vasopressors 
improve cardiac output and increase systemic 
blood pressure above that in the pulmonary artery. 
Noradrenaline has been shown to have beneficial 
effects in infants with PPHN [67]. Milrinone is 
increasingly used due to its additional phosphodi-
esterase (PDE) 3 inhibitor effects.
Various additional treatments for PPHN have 
been tried but are not used routinely. Surfactant 
and magnesium sulphate may be used in selected 
cases. Inhibiting the breakdown of GMP with a 
PDE5 inhibitor such as sildenafil, or cyclic AMP with 
a PDE3 inhibitor such as milrinone can contribute 
towards reducing PVR. Prostacyclin and tolazoline 
are less favoured due to their side effects.
Failure of conventional treatment results in the 
need for ECMO. Offered at specialist centres this 
form of “lung by-pass” has been successfully uti-
lised in infants with reversible disease [68].
Prognosis
The prognosis for infants with PPHN is variable. 
The underlying cause has a significant impact 
upon survival rates. At 2 years of age, survivors 
are noted to have severe neurodevelopment dis-
ability rates of 12% and mild disability rates of 
30% [69].
Meconium aspiration syndrome
Epidemiology and risk factors
The healthy fetus does not normally pass meco-
nium in utero. Fetal distress, usually during labour, 
can cause the fetus to pass meconium into the 
amniotic fluid before delivery. A physiological 
response to worsening fetal distress is for the 
fetus to attempt gasping respiratory effort. During 
such gasps the fetus may inhale meconium 
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stained liquor into the lungs. The inhaled meco-
nium adversely affects the lung in several ways:
●● Mechanical obstruction of the airways leading 
to ventilation/perfusion mismatch
●● Chemical pneumonitis
●● Infection
The resulting inflammatory reaction causes swell-
ing which may block small airways; cause surfactant 
dysfunction; impair gaseous exchange and result in 
PPHN. Risk factors for meconium aspiration syn-
drome (MAS) are any factor increasing the risk or 
indicating the presence of fetal distress; post-term 
gestational age, reduced Apgar score, oligohydram-
nios and male sex [14]. Ethnicity may also affect risk 
of meconium staining of amniotic fluid [70].
One study demonstrated 0.43 per 1000 live 
births suffered from MAS requiring intubation 
[70]. There is evidence that the rates of meconium 
aspiration syndrome have fallen over the past 
decades, possibly due to improved antenatal care.
Clinical aspects
Most infants who have passed meconium in utero 
are asymptomatic, but a period of observation in 
hospital is routine. MAS is suspected in an infant 
with respiratory distress where meconium stain-
ing of the liquor has been noted. Respiratory dis-
tress will usually be present at or soon after birth. 
Infants may also suffer from the effects of in utero 
compromise and may display concurrent signs of 
hypoxic ischaemic encephalopathy including con-
vulsions. The chest radiograph may show patchy 
changes, as seen in figure 1d.
Management of infants with MAS is largely 
supportive therapy while the lung inflamma-
tion resolves. The level of respiratory support will 
depend on severity but high frequency oscillatory 
ventilation or even ECMO may be required in severe 
cases. PPHN may develop, and should be man-
aged as detailed above. Antibiotic therapy should 
be given routinely due to increased risk of infection.
Endogenous surfactant is thought to be inac-
tivated by inhaled meconium and there is some 
evidence of benefit for exogenous surfactant ther-
apy for MAS infants [71]. Lung lavage using diluted 
surfactant to wash out meconium from the lungs, 
has limited evidence of beneficial effect, with 
more studies need before it can be routinely rec-
ommended [72].
Outcomes
6.6% mortality is reported for infants requiring 
ventilation for MAS with 2.5% directly attributed 
to the respiratory system [70]. When all live births 
are studied mortality rates range between 0.96–
2.00 per 100 000 live births [70, 73]. Evidence of 
an improving trend in mortality exists, in line with 
the falling incidence of MAS [73].
Pneumothorax
Epidemiology and risk factors
A pneumothorax is a leak of air from the lungs into 
the pleural cavity. Pneumothorax is the most com-
mon of the air-leak disorders in neonates and can 
occur at any gestation. Most studies report a higher 
risk in preterm infants [74] but a bimodal distribu-
tion with a higher risk in both the most preterms 
and those post-term has also been reported [75]. 
A recent American series showed that 0.56% of all 
births were complicated by pneumothorax, with low 
birth weight infants (<2500 g) at a higher risk [76].
Preterm infants are more likely to have under-
lying respiratory disease (RDS) and to receive 
positive pressure ventilation, both of which are 
associated with increased risk of developing a 
pneumothorax [75]. Unsurprisingly, the risk of 
an air leak is increased in term infants needing 
resuscitation and/or positive pressure ventilation, 
meconium aspiration and large birth weight [75].
Diagnosis and management
A spectrum of severity exists from an asymptom-
atic small pneumothorax that may be noted inci-
dentally on chest radiograph, to a large tension 
pneumothorax causing critical respiratory failure. 
Diagnosis is made by chest radiograph, but using 
a fibre-optic light to transiluminate the chest 
can be useful in critical situations. Management 
depends on severity. A small pneumothorax will 
resolve spontaneously without intervention; how-
ever, a tension pneumothorax requires urgent 
decompression by needle thoracocentesis, prior 
to insertion of a chest drain. Administration of 
100% oxygen to term infants to aid reabsorption 
of a pneumothorax is not effective [77].
Outcomes
In early preterm neonates, pneumothorax is 
associated with an increased risk of mortality 
and intraventricular haemorrhage, with the sub-
sequent risk of developing chronic lung disease 
being controversial [75, 78]. One study found 
no increase in mortality from a pneumothorax in 
term infants [75].
Congenital pneumonia
Epidemiology and risk factors
Congenital pneumonia is responsible for 4.5 neona-
tal deaths per 100 000 birth per year in the UK [79]. 
Pneumonia, like neonatal sepsis, is described as 
being either early or late onset. Early onset, or con-
genital, pneumonia is associated with trans-placen-
tal infection and presents within 48 h of age [80]. 
Viruses, bacteria and fungi are all associated with 
congenital pneumonia, the most common organ-
ism responsible being group B streptococcus [81]. 
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Chorioamnionitis is a major contributory factor for 
sepsis, with infected uterine fluid being inhaled by 
the fetus, potentially resulting in pneumonia [80]. 
Current guidelines support the administration of 
intrapartum antibiotics for chorioamnionitis, whilst 
prolonged rupture of membranes greater than 18 h 
is deemed a risk factor, and in isolation would not 
warrant antibiotics [82].
Congenital pneumonia has similar risk factors 
to neonatal sepsis. The UK National Institute for 
Health and Clinical Excellence guideline on early 
onset neonatal sepsis [83] identify risk factors to 
guide management:
●● Invasive group B streptococcal infection in a 
previous baby
●● Maternal group B streptococcal colonisation, 
bacteriuria or infection in the current pregnancy
●● Prelabour rupture of membranes
●● Preterm birth following spontaneous labour 
(before 37 weeks’ gestation)
●● Suspected or confirmed rupture of membranes 
for more than 18 h in a preterm birth
●● Intrapartum fever higher than 38°C or con-
firmed or suspected chorioamnionitis
●● Parenteral antibiotic treatment given to the 
woman for confirmed or suspected invasive 
bacterial infection (such as septicaemia) at 
any time during labour, or in the 24-h periods 
before and after the birth
●● Suspected or confirmed infection in another 
baby in the case of a multiple pregnancy
Newborn infants are also susceptible to late 
onset pneumonia. This is classified as onset >48 h 
of age. This occurs most commonly in infants 
admitted to a neonatal unit and is often associ-
ated with mechanical ventilation. The spectrum 
of likely causative organisms differs to early onset 
infection as late onset infection is considered to 
be hospital acquired, and therefore the choice of 
antibiotics used for treatment will differ.
Clinical aspects
Presentation of neonates who have congenital 
pneumonia is similar to those with sepsis. Signs 
of respiratory distress may be accompanied by 
temperature instability, but clinical signs of pneu-
monia are very difficult to elicit on examination 
in a neonate. Chest radiograph can show patchy 
consolidation with air bronchograms and a lobar 
distribution of consolidation, but may be initially 
normal. Markers of inflammation such as C-re-
active protein and white blood cell count are 
unreliable in diagnosing infection in the neonatal 
population, and normal values should not be reas-
suring in an unwell infant.
Antibiotic treatment is the mainstay of treat-
ment. Microbiological cultures obtained from the 
mother or infant can be useful in guiding treat-
ment, although often no causative organism is 
identified. Supportive interventions such as oxy-
gen and mechanical ventilation may be required.
The consequences of any neonatal infection 
can be overwhelming. Organ failure may ensue 
and intensive care support may be required. Neo-
nates are prone to sepsis and can deteriorate 
rapidly. Early identification and treatment with 
antibiotics is vital in reducing mortality and mor-
bidity. This is reflected in the guidance that antibi-
otics must be commenced within 1 h of decision 
to treat [83].
Prognosis
The outcomes of neonates with pneumonia vary 
greatly and are dependent upon the organism and 
its virulence. However, early identification and 
treatment of neonates at risk of infection or with 
symptoms of infection reduces both morbidity and 
mortality. A worse prognosis is seen in infants with 
low birth weights and for those with intrauterine 
compared to those with later onset disease [80].
Surgical and congenital conditions
Congenital anomalies within the airways and 
lungs may require surgical correction. The most 
common problems are:
●● Congenital diaphragmatic hernia (CDH)
●● Congenital pulmonary airway malformation 
(CPAM)
●● Tracheo-oesophageal fistula (TOF)
Detailed reviews of these conditions are available 
elsewhere [84–86] including two recent European 
Respiratory Society Task Force reviews on CDH and 
CPAM [87, 88].
Congenital diaphragmatic hernia
CDH was recently the focus of a recent European 
Respiratory Society task force review [87]. One in 
2500 live births is affected by CDH [89]. A develop-
mental failure of the diaphragm during its embry-
ological formation allows herniation of abdominal 
organs into the chest affecting lung growth and 
alveolar development. Many genetic syndromes 
and chromosomal abnormalities are associated 
with CDH [84], but the underlying pathogenesis and 
pathophysiology are poorly understood. Antenatal 
diagnosis is made in 59% of cases [90] permitting 
delivery in a surgical centre. A chest radiograph of a 
left-sided CDH is shown in figure 2a.
Surgical correction of the diaphragmatic defect 
is required, usually undertaken after a period 
of respiratory stabilisation allowing pulmonary 
pressures to fall. ECMO has been used pre- and 
peri-operatively in cases of CDH when optimising 
ventilation is insufficient to overcome the respira-
tory failure. However this approach remains con-
troversial [87].
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Some reports suggest survival rates have 
shown an improving trend over recent years with 
in excess of 80% undergoing surgery surviving 
to discharge [92]; however when all cases are 
considered, the mortality rate remains between 
42–68% [84].
Congenital pulmonary airway malformation
CPAM, also often still called congenital cystic 
adenomatous malformation of the lung (CCAM), 
affects one in 10 000 to one in 35 000 births [85]. 
Most cases are diagnosed by antenatal ultra-
sound scan. Large lesions are associated with 
 polyhydramnios due to compression of the fetal 
oesophagus, impairing swallowing of amniotic 
fluid. Histologically, an overlap exists between 
CPAM and lung sequestration, a condition when a 
portion of the lung is not connected to the bron-
chial tree. A mixed picture is described of seques-
tration containing areas of CPAM [93]. A spectrum 
of postnatal clinical presentation exists from 
asymptomatic, to the infant in respiratory failure 
due to the mass effect of a large lesion or second-
ary pulmonary hypoplasia. Initial investigations 
should include a chest radiograph after delivery, 
and a CT scan prior to surgery. An example of a CT 
scan of a large left sided CPAM is given in figure 2b.
Guidelines suggest that even asymptomatic 
infants should have lesions excised within the 
first 6 months of life to avoid the risk of  malignant 
transformation but excision of asymptomatic 
lesions remains controversial [94, 95] Other 
risks associated with a CPAM are pneumothorax, 
pneumonia and haemoptysis. Surgical excision 
can be undertaken via open thoracotomy or by a 
less invasive thoracoscopic approach. The prog-
nosis after excision of a CPAM is generally good 
with the rare complications of air leak, broncho-
pulmonary fistula and sepsis. Elective surgery of 
asymptomatic cases has a lower rate of compli-
cations compared with surgery after symptom 
development [96].
Tracheo-oesophageal fistula
TOF and oesophageal atresia (OA) normally occur 
as part of the same congenital anomaly in about 
1 in 2500 births [97]. The fistula can connect the 
trachea to the proximal portion, distal portion 
or both portions of the oesophagus. In the rare 
H-type fistula TOF is present without oesopha-
geal atresia. Polyhydramnios and a small stom-
ach on antenatal ultrasound scan should raise 
suspicions, but the diagnosis is usually confirmed 
postnatally with a chest radiograph confirming a 
coiled nasogastric tube in the upper pouch of the 
oesophagus (see figure 2c). Clinically, an infant 
will present with drooling of saliva and chok-
ing if feeding is attempted. The H-type fistula 
usually presents later in the neonatal or infancy 
period with evidence of recurrent aspiration. TOF 
and oesophageal atresia can be associated with 
genetic syndromes, most commonly the VACTERL 
(vertebral/anorectal/cardiac/tracheo-oesopha-
geal/renal/limb anomalies) association, but most 
cases are sporadic [86].
Respiratory issues are related to aspiration 
of secretions either due to overflow from the 
 oesophageal pouch or via the TOF. In cases of 
oesophageal atresia this can be minimised by place-
ment of a dual lumen Replogal tube in the upper 
pouch to allow flushing and suctioning of secretions. 
Definitive management is by surgical correction.
The common respiratory long-term complication 
of TOF is tracheomalacia, resulting in a “TOF cough,” 
usually managed conservatively. Long-term gastro-
intestinal problems such as oesophageal strictures 
and gastro-oesophageal reflux are common.
Rare respiratory disorders in 
the newborn
The most common respiratory disorders affecting 
the neonate have been summarised. A number of 
less common conditions are shown in table 2.
a) b) c)
Figure 2 Radiology images of surgical conditions/congenital anomalies. a) Chest radiograph of infant with large left sided CDH. 
Note presence of bowel and stomach (arrowheads) within the chest. Mediastinal shift to the right. Reproduced from [91] with 
permission from the publisher. b) CT image of left sided CCAM demonstrating large cystic areas and c) chest radiograph demon-
strating coiled nasogastric tube in the upper oesophageal pouch indicating oesophageal atresia. Note gas in stomach indicating 
presence of fistula between distal oesophagus and trachea. b) and c) reproduced from [21] with permission from the publisher.
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Conclusion
The immediate period after birth is crucial to 
the adaption of the infant to extra-uterine life. 
The newborn infant is vulnerable to a range 
of respiratory disorders, all presenting with 
signs of respiratory distress. Thorough clinical 
assessment and appropriate investigation is 
required for all infants presenting with signs of 
 respiratory distress to ensure accurate diagno-
sis and correct treatment. It is important that 
any healthcare professional who comes into 
contact with newborn infants is aware of the 
signs of respiratory distress. Prompt recog-
nition of the more serious underlying condi-
tions is important to improve outcomes. The 
most common causes of respiratory distress 
in preterm and term infants have been sum-
marised along with respiratory conditions 
requiring surgery.
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Table 2 Rare respiratory conditions affecting the newborn
Diagnosis Diagnostic features Notes
Pulmonary complications of disease
Pulmonary haemorrhage Clinical observation of blood from 
endotracheal tube
Usually occurs in ventilated very low birth 
weight infants, or complicating meconium 
aspiration syndrome.
Risk of pulmonary haemosiderosis following 
severe or recurrent episodes.
Pleural effusion (chylothorax) Characteristic chest radiograph 
appearance
Usually consequence of hydrops fetalis or 
chromosomal anomaly. Also iatrogenic, 
following surgical procedure or leak of 
parenteral nutrition from central venous 
catheter. Mortality from underlying cause.
Primary lung disease
Surfactant protein deficiency 
syndromes
Persistent and severe RDS 
presentation in a term infant
Mutations in surfactant proteins or lamellar 
body associated transport protein result in 
lethal respiratory distress due to deficiency in 
surfactant activity.
Alveolar capillary dysplasia Features of severe PPHN, resistant 
to treatment
Diagnosis made at post mortem, with evidence 
of developmental failure of alveoli and 
reduced capillary density. Approaching 100% 
mortality.
Pulmonary Hypoplasia Respiratory failure from birth. Small 
volume lungs on chest radiograph
Primary pulmonary hypoplasia rare, 
more commonly secondary to severe 
oligohydramnios, exomphalos or space 
occupying lesion in the chest (CDH or CPAM) 
Diagnosis confirmed at post mortem.
Congenital malformations
Pulmonary sequestration Large lesions detected antenatally. 
May present with hydrops fetalis.
Older child presents with chronic 
cough or recurrent pneumonia.
Portion of lung not connected to bronchial 
tree. Can be associated with CDH or cardiac 
anomaly. Surgical excision recommended 
for symptomatic lesions, intervention for 
asymptomatic lesions is controversial.
Lobar emphysema Large bullous cystic area on chest 
radiograph
Hyperinflation of one or more lobes 
compressing surrounding structures. 
Lobectomy required for symptomatic cases.
Choanal atresia Inability to pass nasogastric tube. 
Apnoea and cyanosis when not 
crying (bilateral choanal atresia)
50% of cases part of CHARGE syndrome. 
Bilateral atresia cases require urgent surgery 
to create airway.
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